Farglitazar

Farglitazar
Clinical data
Pregnancy; category	N/A;
ATC code	none;
Legal status
Legal status	Development discontinued;
Identifiers
	IUPAC name N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine;
CAS Number	196808-45-4 ;
PubChem CID	170364;
IUPHAR/BPS	2672;
ChemSpider	148961 ;
UNII	3433GY7132;
KEGG	D04132;
ChEMBL	ChEMBL107367 ;
CompTox Dashboard (EPA)	DTXSID1047310 ;
Chemical and physical data
Formula	C34H30N2O5
Molar mass	546.623 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5;
	InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ; Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ;
	(what is this?) (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.^[1] After reaching phase III for type 2 diabetes, further development was discontinued.^[2]^[3]

References

^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
^ "Farglitazar". pharmacodia.com.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.